Barclays upgraded Cronos Group from Underweight to Equal Weight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/2/2022 | $3.00 | Mkt Perform | Bernstein |
| 7/28/2022 | Hold → Buy | Canaccord Genuity | |
| 5/11/2022 | Neutral → Sector Outperform | CIBC | |
| 3/22/2022 | Underweight → Equal Weight | Barclays | |
| 3/7/2022 | $4.00 → $3.00 | Neutral | Piper Sandler |
| 2/22/2022 | $7.00 → $4.25 | Sell | Canaccord Genuity |
| 2/22/2022 | $7.00 → $4.00 | Neutral | Piper Sandler |
| 1/27/2022 | $5.54 → $3.24 | Underperform → Hold | Jefferies |
SC 13D/A - Cronos Group Inc. (0001656472) (Subject)
SC 13D/A - Cronos Group Inc. (0001656472) (Subject)
TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, today announced the appointment of Anna Shlimak as Chief Financial Officer, effective today. Ms. Shlimak, who previously served as Cronos' Chief Strategy Officer, will succeed James Holm who is stepping down to pursue other opportunities and will remain with the Company through April 18, 2025 to ensure a seamless transition. Ms. Shlimak has been an integral part of Cronos' leadership team for the last seven years, playing a key role in shaping the Company's strategy, operational efficiencies, and engagement with the financial and
TORONTO, July 22, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") announces that at its Annual Meeting of Shareholders (the "Meeting") reconvened July 19, 2024, approximately 98.6% of shareholders voting in person or by proxy approved the appointment of Davidson & Company LLP as the Company's independent auditor for fiscal year 2024 and authorized the Board of Directors of the Company to fix the independent auditor's remuneration. For complete results on all matters voted on at the Meeting, please see the Report of Voting Results filed on the Company's SEDAR+ profile at www.sedarplus.com and the Company's Form 8-K filed on EDGAR at www.sec.g
TORONTO, June 21, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") announces that at its Annual Meeting of Shareholders held yesterday, June 20, 2024 (the "Meeting"), shareholders holding a total of 274,097,252 common shares of the Company voted in person or by proxy, representing 71.75% of the total number of common shares of the Company outstanding. Each of the directors listed as a nominee in the Company's definitive proxy statement dated April 26, 2024 was elected as a director of the Company, with each director receiving in excess of 93.4% of the votes cast in favor of his or her election. The detailed results of the vote for the electio
8-K - Cronos Group Inc. (0001656472) (Filer)
10-K - Cronos Group Inc. (0001656472) (Filer)
8-K - Cronos Group Inc. (0001656472) (Filer)
4 - Cronos Group Inc. (0001656472) (Issuer)
4 - Cronos Group Inc. (0001656472) (Issuer)
4 - Cronos Group Inc. (0001656472) (Issuer)
TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc.'s (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") best-selling cannabis brand, Spinach®, is thrilled to introduce three all-new 1.2g vape products, each expertly crafted with premium THC and enhanced with rare cannabinoids for a uniquely elevated experience. Along with these innovative vape offerings, Cronos is also unveiling new SOURZ by Spinach® Fully Blasted flavors, infused with rare cannabinoids. The new lineup includes three new 1.2 gram vapes in the following formats: Mango Kiwi Haze CBC (Sativa): A refreshing, uplifting blend with a 1:10 CBC-to-THC ratio.Peach Passionfruit Kush CBN (Indica): A dreamy, restful expe
TORONTO, March 19, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, today announced the appointment of Anna Shlimak as Chief Financial Officer, effective today. Ms. Shlimak, who previously served as Cronos' Chief Strategy Officer, will succeed James Holm who is stepping down to pursue other opportunities and will remain with the Company through April 18, 2025 to ensure a seamless transition. Ms. Shlimak has been an integral part of Cronos' leadership team for the last seven years, playing a key role in shaping the Company's strategy, operational efficiencies, and engagement with the financial and
TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company"), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President and CEO, will speak at the 37th Annual Roth Conference on Monday, March 17, 2025, at 1:00 PM PT. A live webcast will be available on the Investors section of the Company's website at https://ir.thecronosgroup.com/events-presentations. About Cronos Group Inc.Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consum
TORONTO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2024 fourth-quarter and full-year earnings conference call on Thursday, February 27, 2025 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be arch
TORONTO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2024 third quarter earnings conference call on Tuesday, November 12, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay
TORONTO, July 25, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2024 second quarter earnings conference call on Thursday, August 8, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay o
Bernstein initiated coverage of Cronos Group with a rating of Mkt Perform and set a new price target of $3.00
Canaccord Genuity upgraded Cronos Group from Hold to Buy
CIBC upgraded Cronos Group from Neutral to Sector Outperform